|Title:||Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management||Authors:||Park D.I.
|Keywords:||anti-TNF; consensus statement; inflammatory bowel disease; tuberculosis||Issue Date:||2018||Publisher:||Blackwell Publishing||Journal Volume:||33||Journal Issue:||1||Start page/Pages:||30-36||Source:||Journal of Gastroenterology and Hepatology (Australia)||Abstract:||
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised three parts: (3) management of latent TB in preparation for anti-TNF therapy, (4) monitoring during anti-TNF therapy, and (5) management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment. ? 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
|ISSN:||0815-9319||DOI:||10.1111/jgh.14018||SDG/Keyword:||tumor necrosis factor inhibitor; adalimumab; immunosuppressive agent; infliximab; monoclonal antibody; tuberculostatic agent; chemotherapy; consensus development; human; inflammatory bowel disease; latent tuberculosis; patient monitoring; priority journal; Review; treatment duration; antibiotic prophylaxis; Asia; combination drug therapy; complication; consensus; gastroenterology; inflammatory bowel disease; organization and management; treatment outcome; tuberculosis; Adalimumab; Antibiotic Prophylaxis; Antibiotics, Antitubercular; Antibodies, Monoclonal; Asia; Consensus; Drug Therapy, Combination; Gastroenterology; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Infliximab; Treatment Outcome; Tuberculosis
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.